Adare Pharmaceuticals
Princeton Pike Corporate Center

1200 Lenox Drive, Suite 100
Lawrenceville, NJ 08648


Adare Pharmaceuticals is a global specialty CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets.  Adare’s proprietary technology platforms specialize in ODT, taste masking and customized drug release.

With over 30 years of proven legacy, Adare has successfully developed and manufactured more than 40 products sold by partners in more than 100 countries globally.


Adare Pharmaceuticals has four sites located in the US and Europe with over 600 employees worldwide.  With our global R&D and manufacturing capabilities, in-house regulatory and clinical support, we have the expertise to take your project from formulation development through commercial scale manufacturing.  Our sites are compliant with cGMP criteria and approved to handle controlled substances and solvents, and maintain excellent environmental credentials.  Our in house regulatory and quality teams have a proven global track record with the FDA, AIFA in Italy, EMA in Europe and ANVISA for Brazil.


Adare has recently launched a new patient centric dosage solution, the Parvulet TM Technology. The Parvulet TM Technology enables a solid powder or tablet to convert to a semi-solid in the presence of water within thirty seconds. The final dosage is easily administered, as a soft food like texture, ideal for pediatric and geriatric populations (including those with dysphagia). The ParvuletTM technology can be combined with our other proprietary technologies, providing multiple ways to provide more patient centric solutions.


Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The completely encapsulated particle allows for a pleasant mouthfeel without an aftertaste. The Microcaps technology can be applied to multiple dosage forms and immediate and modified release profiles.

AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who have difficulty swallowing, pediatric, geriatric, and dysphagic patients. This technology can be combined with Microcaps® and Diffucaps® to create IR or controlled-release ODTs.

Diffucaps® Customized Release Technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This allows for easy adjustment of both dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile. Beads can have different release profiles, different active ingredients, or both—all in one product.

MMTSTM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets—a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule.

BIORISETM Bioavailability Enhancement Technology breaks down drug particles to their thermodynamically activated form to increase solubility profiles. New physical entities are created by breaking down the crystalline drug into nanocrystals and/or amorphous particles. This process allows for oral dosing for poorly soluble drugs and can be applied to class II compounds with less than 10 to 500 μg/mL solubility.